CAAA603B12101 NeoB BC
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative and Gastrin Releasing Peptide Receptor Positive Breast Cancer Experiencing Early Relapse From (Neo)Adjuvant Endocrine Therapy
Detalhes
Destaques